| 8.53 0.13 (1.55%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.11 | 1-year : | 11.81 |
| Resists | First : | 8.65 | Second : | 10.11 |
| Pivot price | 8.17  |
|||
| Supports | First : | 7.6 | Second : | 6.96 |
| MAs | MA(5) : | 8.34 |
MA(20) : | 8.07 |
| MA(100) : | 7.16 |
MA(250) : | 6.04 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 82.4 |
D(3) : | 79.4 |
| RSI | RSI(14): 65.8 |
|||
| 52-week | High : | 8.65 | Low : | 3.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PBYI ] has closed above the upper band by 1.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.65 - 8.68 | 8.68 - 8.71 |
| Low: | 8.19 - 8.23 | 8.23 - 8.26 |
| Close: | 8.46 - 8.53 | 8.53 - 8.59 |
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Wed, 08 Jul 2026
PUMA Biotechnology (PBYI) officer Douglas Hunt sells 8,460 shares under 10b5-1 plan - Stock Titan
Wed, 08 Jul 2026
Puma Biotechnology (PBYI) CFO sells 9,386 shares in 10b5-1 trade - Stock Titan
Wed, 08 Jul 2026
Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan - Stock Titan
Fri, 03 Jul 2026
Puma Biotechnology highlights targeted cancer therapies as investors watch Nasdaq-listed PBYI - ad-hoc-news.de
Fri, 03 Jul 2026
PBYI Should I Buy - Intellectia AI
Sun, 28 Jun 2026
PBYI Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 15.4 (%) |
| Held by Institutions | 75 (%) |
| Shares Short | 3,630 (K) |
| Shares Short P.Month | 3,800 (K) |
| EPS | 0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.51 |
| Profit Margin | 10.7 % |
| Operating Margin | -8.6 % |
| Return on Assets (ttm) | 9.4 % |
| Return on Equity (ttm) | 21.6 % |
| Qtrly Rev. Growth | -2.6 % |
| Gross Profit (p.s.) | 3.32 |
| Sales Per Share | 4.46 |
| EBITDA (p.s.) | 0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 54 (M) |
| Levered Free Cash Flow | 44 (M) |
| PE Ratio | 17.77 |
| PEG Ratio | 0 |
| Price to Book value | 3.38 |
| Price to Sales | 1.91 |
| Price to Cash Flow | 8.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|